You are here: Home > Cannabinoids (former) > Cannabinoids in cancer pain

Cannabinoids 2010;5(1):1-3 (January 23, 2010)

Article of the Month

Cannabinoids in cancer pain

Franjo Grotenhermen

nova-Institut, Chemiepark Knapsack, Industriestraße, D-50354 Hürth, Germany, franjo.grotenhermen@nova-institut.de

This article of the month presents results of a clinical study conducted in the UK and Romania, which evaluated the efficacy of a THC:CBD cannabis extract (Sativex®) and a THC cannabis ex-tract in the treatment of 177 patients with cancer pain, who experienced inadequate pain reduction despite intake of opioids [Johnson et al. J Pain Symptom Manage, 2010, in press]. Sativex resulted in a significant improvement of mean pain scores on a primary outcome measure, a Numerical Rating Scale (NRS) from 0 to 10 compared to placebo (improvement of -1.37 versus -0.69), while the THC extract caused a non-significant improvement (-1.01). Conversely, there was a significant improvement in total pain according to the Brief Pain Inventory-Short Form in the THC-group compared to placebo but a non-significant improvement following Sativex.

Keywords
cannabis, THC, cannabidiol, chronic pain, cancer, clinical trial.

PDF of the full text ]

Online Events 2020

Please find all information of IACM Online Events including free videos of the webinars here.

Virtual Conference 2021

The 12th IACM Conference on Cannabinoids in Medicine will be held online from 14 to 16 October 2021. Registration is for free.

Members only

Regular members can sign up for the new member area of the IACM to access exclusive content.

You need to become a regular member of the IACM to access the new member area.

IACM on Twitter

Follow us on twitter @IACM_Bulletin where you can send us inquiries and receive updates on research studies and news articles.